Status Epilepticus
78
19
19
36
Key Insights
Highlights
Success Rate
84% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
9.0%
7 terminated out of 78 trials
83.7%
-2.8% vs benchmark
19%
15 trials in Phase 3/4
22%
8 of 36 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 36 completed trials
Clinical Trials (78)
Recovery Trajectory for Coma and Disorders of Consciousness
Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis
Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)
EEG Monitoring for Refractory Status Epilepticus
Improving Status Epilepticus Treatment Times
Status Epilepticus in Men and Women: Clinical Presentation, Management, and Outcomes
Augmented Renal Clearance in Neurocritical Care
Targeted Hypothermia Versus Targeted Normothermia After Convulsive Refractory Status Epilepticus
Comparison of Intravenous Brivaracetam Versus Levetiracetam in the Management of Status Epilepticus
Point-of-care EEG in the Pediatric Emergency Department
Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest
Simulation Trial of Telemedical Support for Paramedics
Comparison of Narcotrend and Cerebral Function Analysing Monitor in Intensive Care to Monitor Seizures and Deep Sedation
PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest
Efficacy Comparison Between Levetiracetam and Valproic Acid in Pediatric Patients With Status Epilepticus
Improving Outcomes for Patients With Life-Threatening Neurologic Illness
De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information
Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus
Randomized Therapy In Status Epilepticus
buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest